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Abstract 
Sirtuins  are  highly  conserved  NAD
+-dependent  protein  deacetylases  and/or 
ADP-ribosyltransferases that can extend the lifespan of several lower model organisms in-
cluding yeast, worms and flies. The seven mammalian sirtuins, SIRT1 to SIRT7, have emerged 
as key metabolic sensors that directly link environmental signals to mammalian metabolic 
homeostasis and stress response. Recent studies have shed light on the critical roles of 
sirtuins in mammalian energy metabolism in response to nutrient signals. This review focuses 
on the involvement of two nuclear sirtuins, SIRT1 and SIRT6, and three mitochondrial sirtuins, 
SIRT3, SIRT4, and SIRT5, in regulation of diverse metabolic processes. 
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Introduction 
Yeast silent information regulator 2 (Sir2) protein 
and its homologues in other prokaryotes and eukary-
otes,  also  known  as  sirtuins,  are  highly  conserved 
NAD+-dependant  protein  deacetylases  and/or 
ADP-ribosyltransferases (1-3). In yeast, Sir2 is of great 
importance in the maintenance of the silent chromatin 
at  the  mating-type  loci,  telomeres,  and 
rRNA-encoding  DNA  repeats  (reviewed  in  (4)). 
However,  sirtuins  in  other  model  organisms  have 
been increasingly recognized as crucial regulators for 
a variety of cellular processes, ranging from energy 
metabolism and stress response to tumorigenesis and 
aging (5).  
About a decade ago, Sir2 was first implicated as 
a limiting component of yeast longevity (6, 7). Since 
then, many members of this family have been identi-
fied  as  key  longevity  regulators  in  species  ranging 
from yeast to fly (reviewed in (8, 9)). For example, in 
S.  cerevisiae,  deletion  of  the  Sir2  gene  dramatically 
shortens lifespan, whereas an extra copy of the Sir2 
extends lifespan by 40% (7). In C. elegans, overexpres-
sion of Sir2.1, a Sir2 homologue, extends lifespan by 
up to 50% (10). Similar results are seen in Drosophila 
(11). The mammalian genome encodes seven sirtuins, 
named  SIRT1  to  SIRT7  (12).  Currently,  the  role  of 
mammalian sirtuins in the regulation of mammalian 
aging is an area of intense research.   
The seven mammalian sirtuin proteins share a 
highly  conserved  NAD+-binding  and  catalytic  core 
domain, but have distinct flanking N- and C-terminal 
extensions (12) (Figure 1). Many mammalian sirtuins 
bears a NAD+-dependant protein deacetylase activity. 
A variety of acetyl-proteins have been identified as 
their substrates at different physiological and patho-
logical conditions (Table 1), although whether p53 is a 
true substrate for SIRT7 is still not clear. The only re-
ported  activity  of  SIRT4,  on  the  other  hand,  is  the 
NAD+-dependant ADP-ribosyltransferase activity (13, 
14).  The  divergent  N  and  C-termini  of  sirtuins  are 
responsible for their variation binding partners, sub-
strates,  and  subcellular  localization  ((9),  Figure  1). 
Three of the mammalian sirtuins, SIRT1, SIRT6, and 
SIRT7, are nuclear proteins (Figure 1). SIRT1, while 
predominately  a  nuclear  enzyme,  can  also  shuttle Int. J. Biol. Sci. 2011, 7 
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between cytosol and nucleoplasm in various tissues in 
response  to  different  environmental  signals  (15). 
SIRT6  is  a  nuclear,  chromatin-bound  protein  (16), 
whereas SIRT7 is highly enriched in nucleolus (17). 
Three additional mammalian sirtuins, SIRT3, SIRT4, 
and SIRT5, are found in mitochondria. They partici-
pate in a number of metabolic and survival processes 
associated with the mitochondrial activity (reviewed 
in (18)). The other mammalian sirtuin, SIRT2, is pri-
marily cytosolic.  
 
 
Figure 1. Schematic representation of seven mammalian sirtuins. 
 
 
 
Table 1. Mammalian sirtuins. Abbreviations: p53, tumor suppressor protein 53; Foxo, forkhead box O; Bax, Bcl2 
associated X protein; Hif, hypoxia-inducible factor; HSF1, heat shock factor 1; STAT3, signal transducer and activator of 
transcription 3; PGC-1, peroxisome proliferator-activated receptor gamma coactivator 1; NF-B, nuclear factor-kappa 
B; TORC2/CRTC2, a transcriptional coactivator for the transcription factor CREB; LXR, liver X receptor; FXR, farnesoid X 
receptor; SREBP, sterol regulatory element binding protein; PER2, period circadian protein homolog 2; H4, histone 4; 
AceCS2, acetyl-CoA synthetase 2; LCAD, long-chain acyl CoA dehydrogenase; HMG-CoA synthase 2, 
3-hydroxy-3-methylglutaryl CoA synthase 2;  IDH2, isocitrate dehydrogenase 2; MnSOD, Mn-superoxide dismutase; SOD2, 
superoxide dismutase 2; GDH, glutamate dehydrogenase; CPS1, carbamoyl phosphate synthetase 1; CtIP, C-terminal 
binding protein interacting protein; H3K9, histone 3 acetyl-lysine 9; H3K56, histone 3 acetyl-lysine 56; CtIP, C-terminal 
binding protein interacting protein. 
Sirtuin  Activity  Substrates  Functions  References 
SIRT1  Deacetylase  p53, Foxo1, Foxo3, Bax, Hif-1,  
Hif-2a, HSF1, Ku70,  b-catenin, 
E2F1, Myc, STAT3, PGC-1a, 
NF-B, TORC2, LXR, FXR, SREBP, 
PER2, CLOCK 
Energy metabolism, stress 
response 
 Reviewed in (9) 
SIRT2  Deacetylase  Tubulin, H4, Foxo3a  Cell cycle   (123-125) 
SIRT3  Deacetylase  Oxidative phosphorylation com-
plex I, AceCS2, LCAD,  
HMG-CoA synthase 2, IDH2, 
MnSOD, SOD2 
ATP production, an-
ti-oxidative stress, ther-
mogenesis 
 (35, 36, 104-109) 
SIRT4  ADP-ribosyl-transferase  GDH  Insulin secretion, fatty acid 
oxidation 
 (13) 
SIRT5  Deacetylase  CPS1  Urea cycle   (117) 
SIRT6  Deacetylase/ADP-ribosyl-transferase  H3K9, H3K56, CtIP, SIRT6  DNA repair, metabolism, 
inflammation 
 (89-92) 
SIRT7  Deacetylase?  p53?  rDNA transcription   (17, 126) 
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Regulation of sirtuins in Calorie Restriction 
Despite  diverse  subcellular  localizations  and  a 
broad range of substrate specificities, the activity of all 
sirtuins is directly controlled by cellular NAD+ levels, 
which is an indicator of cellular metabolic status. The 
activity  of  these  enzymes  is  also  inhibited  by  their 
common enzymatic product, nicotinamide  (19), and 
possibly by NADH (20). It is therefore not surprising 
that  the  activity  of  sirtuins  changes  in  response  to 
environmental  cues  that  impact  cellular  metabolic 
state.  A  prominent  example  of  this  is  Caloric  Re-
striction  (CR),  a  20–40%  reduction  in  calories  con-
sumed below ad libitum intake without malnutrition. 
CR has been shown to extend the median and maxi-
mum  life  span  of  numerous  organisms  including 
yeast, flies, worms, fish, as well as rodents and other 
higher mammals (21). In mammals, CR has been seen 
to ameliorate many of the pathologies associated with 
obesity and metabolic syndrome (22, 23).   
CR  is  thought  to  promote  lifespan  extension 
through  multiple  signaling  pathways.  On  the  one 
hand,  CR  decreases  the  activity  of  pro-aging  path-
ways such as insulin and growth hormone signaling 
and oxidative stress. On the other hand, CR stimulates 
the activity of cellular stress-resistance pathways in-
cluding DNA repair and autophagy (24, 25), promot-
ing cell survival in response to environmental stress. 
It has been shown that in yeast, CR reduces cellular 
NADH  concentrations,  thereby  increasing  the 
NAD+/NADH ratio and promoting Sir2 activity (20). 
In a number of lower model organisms, sirtuins are 
required for the lifespan extension provided by CR 
(11, 26). Whether sirtuins mediate the life-extending 
effects of CR in mammals is currently an area of great 
interest.  Recent  studies  have  shown  that  in  mice, 
SIRT1  protein  levels  are  elevated  during  CR  in  the 
brain, white adipose tissue (WAT), muscles, liver, and 
kidney  (27,  28).  CR  also  induces  the  expression  of 
SIRT3, particularly in brown adipose tissue (BAT) (29, 
30). However, during CR in mice, cellular NAD+ lev-
els and the NAD+/NADH ratio fluctuate significantly 
depending on tissue type (31), suggesting that sirtuins 
have tissue-specific responses to CR. Nevertheless, it 
appears that SIRT1 regulates energy metabolism and 
physical responses to CR (32-34), while SIRT3 is able 
to  mediate  CR-associated  reduction  of  oxidative 
damage, preventing age-associated hearing loss (35, 
36).  Moreover, transgenic mice overexpressing SIRT1 
display multiple phenotypes resembling those of CR 
mice, including lower body weight, greater metabolic 
activity, and reduced serum levels of cholesterol, ad-
ipokines, insulin, and glucose (37-39). Taken together, 
these studies highlight the importance of sirtuins in 
CR-mediated prevention of age-associated functional 
decline,  suggesting  that  sirtuins  may  be  important 
therapeutic targets for a number of age-related dis-
eases.  
SIRT1 in energy metabolism 
As  the  best-studied  mammalian  sirtuin,  SIRT1 
has  been  implicated  in  a  variety  of  metabolic  pro-
cesses including hepatic lipid metabolism and gluco-
neogenesis,  pancreatic  insulin  secretion,  fat  cell  ac-
cumulation and maturation, central nutrient sensing, 
as well as circadian regulation of metabolism. Further 
elucidation of the role SIRT1 plays in energy metabo-
lism will likely provide key insights into developing 
treatments for obesity-induced metabolic disease. 
1. SIRT1 in hepatic glucose and lipid metabolism  
The liver is a central metabolic organ controlling 
key  aspects  of  lipid  and  glucose  metabolism  in  re-
sponse to nutritional and hormonal signals (40). For 
example, in fasting conditions, the liver converts lipid 
and glycogen stores into available energy through the 
process  of  fatty  acid  -oxidation  and  glycogenoly-
sis/gluconeogenesis. In the fed condition, metabolic 
programs in the liver are switched on to store energy 
in the form of glycogen and lipid droplets.  
Recent reports have shown that SIRT1 is an im-
portant regulator of hepatic glucose and lipid metab-
olism  (Figure  2).  For  instance,  during  short-term 
fasting phase, SIRT1 inhibits TORC2, a key mediator 
of early phase gluconeogenesis, leading to decreased 
gluconeogenesis  (41).  Prolonged fasting leads to in-
creased  SIRT1  deacetylation  and  activation  of 
PGC-1,  an  essential  co-activator  for  a  number  of 
transcription factors, resulting in increased fatty acid 
oxidation and improved glucose homeostasis (42-44). 
SIRT1 also deacetylates and activates transcriptional 
factor Foxo1, resulting in increased gluconeogenesis 
(45).  Consistently,  adenoviral  knockdown  of  SIRT1 
reduces expression of fatty acid -oxidation genes in 
the liver of fasted mice (46).  Specific deletion of the 
exon 4 of the hepatic mouse SIRT1 gene, which re-
sulted  in  a  truncated  non-functional  SIRT1  protein, 
impairs fatty acid -oxidation, thereby increasing the 
susceptibility  of  mice  to  high-fat  diet  induced 
dyslipidemia,  hepatic  steatosis,  inflammation  and 
endoplasmic reticulum (ER) stress (43).  A complete 
deletion  of  hepatic SIRT1  by floxing  exons 5  and  6 
leads to the development of liver steatosis even under 
normal  chow  diet  (47).  Conversely,  hepatic  overex-
pression of SIRT1 mediated by adenovirus attenuates 
hepatic steatosis and ER stress, and restores glucose 
homeostasis in mice (48), confirming the essential role Int. J. Biol. Sci. 2011, 7 
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of SIRT1 in maintaining hepatic metabolic homeosta-
sis.  
SIRT1 also regulates hepatic cholesterol and bile 
acid  homeostasis  through  direct  modulation  of  the 
liver  X  receptor  (LXR),  farnesoid  X  receptor  (FXR), 
and  the  sterol  regulatory  element  binding  protein 
(SREBP) family of transcription factors (49-52).  LXR 
and  FXR  are  nuclear  receptors  that  function  as  im-
portant cholesterol and bile acid sensors (53). We have 
previously shown that SIRT1 can directly deacetylate 
LXRs, resulting in increased LXR turnover and target 
gene  expression  (49).  Systemic  deletion  of  SIRT1  in 
mice results in decreased serum HDL levels (49). Re-
cently, Kemper et al. showed that the bile sensor FXR 
is also a target of hepatic SIRT1 in metabolic regula-
tion (50). Acetylation of FXR inhibits its activity and 
downregulation of hepatic SIRT1 increases FXR acet-
ylation, causing deleterious metabolic outcomes such 
as liver steatosis and decreased bile output. Walker et 
al. and Ponugoti et al. further showed that SIRT1 may 
also  regulate  hepatic  lipid  metabolism  through 
deacetylation of SREBPs (51, 52), critical regulators of 
lipid metabolism that promote expression of lipogenic 
and cholesterolgenic genes involved in lipid storage 
(54).  These two reports revealed that SIRT1  can  di-
rectly deacetylate SREBP, and that SIRT1 activity is 
important  in  the  fasting-dependent  attenuation  of 
SREBP  (51,  52).  In  addition,  chemical  activators  of 
SIRT1  inhibit  SREBP  target  gene  expression  in vitro 
and in vivo, correlating with attenuated liver steatosis 
in diet-induced and genetically obese mice. In sum-
mary, these findings imply that hepatic SIRT1 plays a 
critical role in metabolic regulation and activation of 
SIRT1  in  the  liver  may  prove  beneficial  in  treating 
obesity-associated diseases. 
 
 
 
 
 
Figure 2. The diverse functions of SIRT1 in central nutrient sensing and peripheral energy metabolism. The activity of SIRT1 
is regulated by the cellular metabolic status, small molecule activators, interacting proteins, as well as post-translational 
modifications. After activation, SIRT1 modulates a variety of metabolic activities systemically and locally through either 
direct protein deacetylation or indirect chromatin remodeling. 
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2. SIRT1 in fat cell maturation and fat accumu-
lation  
Adipose tissue functions both to store fat and as 
a  conduit  for  hormone  signaling.  For  example, 
WAT-derived hormones such as leptin and adiponec-
tin  control  energy  balance,  glucose  regulation,  and 
fatty  acid  catabolism.  Among  numerous  factors  in-
volved in adipose tissue differentiation, the nuclear 
receptor PPAR plays an essential role in modulating 
fatty acid storage and glucose metabolism (55). SIRT1 
has been shown to repress PPAR, thereby suppress-
ing the expression of genes such as the mouse aP2 
gene  and  fat  storage  ((27),  Figure  2).  Consistently, 
treatment of mice on a high fat diet with resveratrol, a 
polyphenol that activates SIRT1, has been shown to 
protect  against  high-fat  induced  obesity  and  meta-
bolic  derangements  (56-58).  Although  the  mecha-
nisms  of  resveratrol’s  apparent  protective  effect  on 
metabolic  disorders are  not  fully  understood, ques-
tions still remain whether or not resveratrol directly 
activates SIRT1 or functions through multiple signal-
ing pathways (59, 60), these findings demonstrate that 
SIRT1 acts in concert with lipid regulating transcrip-
tion factors to adapt gene transcription to changes in 
nutrient levels.  
 As  an  important  non-shivering  thermogenesis 
organ, brown adipose tissue (BAT) plays an essential 
role  in  survival  of  non-shivering  animals  and  neo-
nates. However, the role of SIRT1 in BAT is still not 
clear. On the one hand, SIRT1 in BAT may directly 
promote  BAT  differentiation  through  repression  of 
the  MyoD-mediated  myogenic  gene  expression  sig-
nature  and  stimulation  of  PGC-1-mediated  mito-
chondrial  gene  expression  (61).  On  the  other  hand, 
SIRT1  also  appears  to  regulate  BAT  differentiation 
and functions through non-cell autonomous mecha-
nisms.  It  has  been  shown  that  SIRT1  in  pro-
piomelanocortin  (POMC)  expressing  neurons  selec-
tively controls perigonadal WAT-to-BAT-like remod-
eling to increase energy expenditure in female mice 
(62). Consistent with these observations, activation of 
SIRT1  by  a  specific  SIRT1  activator,  SRT1720,  en-
hances oxidative metabolism in skeletal muscle, liver, 
and BAT (63). Together, these data indicate that SIRT1 
modulates  BAT  through  both  cell  autonomous  and 
non-cell autonomous mechanisms.  
3. SIRT1 in pancreatic insulin secretion 
Pancreatic  cells are systemic metabolic sensors 
that release insulin in response to blood glucose lev-
els. Dysfunction of these cells is the leading cause of 
type 1 diabetes mellitus, and partially contributes to 
the pathogenesis of type 2 diabetes.  SIRT1 has been 
shown to be a major positive regulator for pancreatic 
insulin secretion, which in turn triggers glucose up-
take and utilization. For example, it has been reported 
that increased dosage of SIRT1 in pancreatic  cells 
improves glucose tolerance and enhances insulin se-
cretion in response to glucose in mice (64), whereas 
deletion of SIRT1 impairs glucose-stimulated insulin 
secretion (65). In both studies, SIRT1 has been shown 
to promote insulin secretion by repressing transcrip-
tion of the uncoupling protein 2 (UCP2) (Figure 2). 
Furthermore, it has been shown that treatment with 
resveratrol  potentiates  glucose-stimulated  insulin 
secretion in  cells (66). In line with these observa-
tions, activation of SIRT1 by its activators in animals 
protects against high-fat induced obesity and insulin 
resistance  (56-58),  and  modest  overexpression  of 
SIRT1 has a protective effect against high-fat induced 
glucose intolerance (38, 39). These observations sug-
gest that modulation of SIRT1 activity may regulate 
whole-body glucose metabolism at both systemically 
and locally. 
4. SIRT1 in central control of metabolic homeo-
stasis 
The brain is essential in controlling whole-body 
metabolism  through  both  neurologic and  endocrine 
functions.  The  hypothalamus/pituitary  axis  is  the 
primary brain structure that interprets adiposity and 
nutrient-related inputs to regulate energy homeosta-
sis. It has been shown that both CR and fasting en-
hance  SIRT1  expression  and  activity  in  the  hypo-
thalamus  (67,  68).  Mice  lacking  SIRT1  in  the  brain 
show specific anterior pituitary cell defects and fail to 
mediate changes in pituitary signaling and physical 
activity in  response  to  CR  (34),  while  brain-specific 
SIRT1 transgenic mice display enhanced neural activ-
ity in the hypothalamus (68). These findings suggest 
that SIRT1 in the brain may function as a link between 
the  hypothalamus/pituitary  hormones  and  CR  lon-
gevity pathways in mammals. 
However, the role of SIRT1 in the central control 
of whole body energy homeostasis is complex (Figure 
2). In the hypothalamus, the anorexigenic POMC ex-
pressing  neurons  and  the  orexigenic  agouti-related 
protein  (AgRP)  expressing  neurons  are  the  major 
regulators  of  feeding  and  energy  expenditure  (69). 
The POMC neurons produce satiety peptides thereby 
inhibiting food intake after feeding, while the AgRP 
neurons promote feeding in response to fasting and 
CR. It appears that SIRT1 plays distinct roles in these 
two neuron populations. A recent study has shown 
that  inhibition  of  hypothalamic  SIRT1  activity  re-
verses the fasting induced decrease of FOXO1 acety-
lation,  resulting  in  increased  POMC  and  decreased Int. J. Biol. Sci. 2011, 7 
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AgRP  expressions,  thereby  decreasing  food  intake 
and body weight gain (67). This hypothalamic activity 
of SIRT1, which is in contrast to its anti-obesity func-
tions in the peripheral tissues, appears to act through 
AgRP neurons, as AgRP neuron-specific deletion of 
SIRT1 decreases AgRP neuronal activity, thereby al-
leviating the inhibitory tone on the POMC neurons, 
resulting in decreased food intake and body weight 
(70).  Specific deletion of SIRT1 in POMC neurons in 
mice, on the other hand, causes a blunted response to 
leptin  signaling  and  reduced  energy  expenditure, 
leading  to  hypersensitivity  to  diet-induced  obesity 
(62). Nevertheless, these studies confirm that SIRT1 is 
an essential element in the periphery-central feedback 
circuits  that  mediate  normal  responses  to  nutrient 
deprivation.  Consistent  with  these  notions,  central 
administration of small molecule SIRT1 activator has 
shown promise in controlling of diet-induced obesity. 
For example, long-term intracerebroventricular infu-
sion  of  resveratrol  normalizes  hyperglycemia  and 
greatly improves hyperinsulinemia in mice with di-
et-induced  obesity  and  diabetes  (71),  although 
resveratrol may elicit its functions through both SIRT1 
dependent and independent pathways. In summary, 
SIRT1 activity appears to be an important player in 
the  central  regulation  of  nutrient  sensing.  As  rela-
tively little is known at this stage, this area of sirtuin 
biology  may  yield  important  discoveries  in  coming 
years.   
5. SIRT1 in the regulation of circadian rhythm 
All living entities on Earth have endogenously 
driven 24-hour  cycles in many biological processes.  
This circadian rhythm depends on internal clocks that 
work  in  part  through  chromatin  modification  and 
epigenetic control of gene expression (72). In mam-
mals, the circadian clock is largely controlled by neg-
ative-feedback loops mediated by the heterodimeric 
transcription factors CLOCK-BMAL1 and their tran-
scriptional targets, including the PER and CRY pro-
teins  that  in  turn  directly  repress  CLOCK-BMAL1 
activity, as well as REV-ERB and ROR nuclear recep-
tors that control BMAL1 expression (73). The CLOCK 
protein itself is a transcriptional activator that func-
tions as a histone acetyltransferase (HAT) (74), high-
lighting the importance of chromatin modification in 
the regulation of circadian gene expression.  
SIRT1 has recently been linked to the regulation 
of the circadian rhythm (Figure 2). Two studies have 
shown that SIRT1 interacts with CLOCK-BMAL1 to 
directly  regulate  the  amplitude  of  circadian 
clock-controlled  gene  expression  through  deacetyla-
tion  of  PER2  and/or  BMAL1  (75,  76).  However, 
whether it is the amount of SIRT1 or its activity that is 
cyclically  regulated  by  the  circadian  clock  remains 
unclear. Two recent studies appear to favor the circa-
dian regulation of SIRT1 activity (77, 78).  The expres-
sion  of  NAMPT,  an  enzyme  that  controls  a 
rate-limiting  step  in  NAD+  biosynthesis,  is  directly 
controlled by CLOCK-BMAL1. It has been proposed 
that  this  regulation  leads  to  circadian  oscillation  of 
cellular NAD+ levels, resulting in a cyclical regulation 
of SIRT1 activity (77, 78). Together, these studies add 
a  new feedback loop in the circadian clock that in-
volves CLOCK-BMAL1, NAMPT, NAD+, and SIRT1, 
and provide an important link between the circadian 
clock and cellular metabolism.  
It  remains  to  be  determined  whether  the  ob-
served oscillation of cellular NAD+ levels (77, 78) is 
indeed responsible for the oscillation of SIRT1 activity 
observed in earlier studies (76). An earlier study had 
shown that the activity of immuno-purified endoge-
nous  SIRT1  proteins  display  a  circadian  oscillating 
pattern when measured in vitro with fixed amount of 
exogenous NAD+ (Figure 1D in (76)), suggesting that 
post-translational  modifications,  or  protein-protein 
interactions also play a role in the circadian regulation 
of SIRT1 activity. SIRT1 has several interacting part-
ners  that  can  directly  inhibit  or  activate  its  activity 
(79-82). Its activity can also be modulated by phos-
phorylation (83-85), particularly by DYRK1A (86), an 
essential clock component that governs the rhythmic 
phosphorylation  and  degradation  of  CRY2  protein 
(87).  Therefore,  exploring  the  possible  role  of  these 
factors  in  the  circadian  regulation  of  SIRT1  activity 
may provide novel insights into its function in circa-
dian rhythm.   
SIRT6 in metabolic homeostasis and inflamma-
tion 
SIRT6, another nuclear sirtuin, plays an essential 
role  in  animal  development.  Previous  studies  have 
shown  that  among  the  seven  mammalian  sirtuins, 
SIRT6 deficiency causes the most striking phenotypes. 
The SIRT6 null mice appear to have normal embry-
onic development and intrauterine growth and were 
born with no obvious abnormalities. However, they 
suffer  a  severe  metabolic  imbalance,  acute  onset  of 
hypoglycemia,  postnatal  growth  retardation,  and 
premature death at one month of age (16). Unlike the 
110  kDa  SIRT1  protein,  SIRT6  is  relatively  small 
(around 36 kDa) with short N- and C-terminal exten-
sions (12). Although it is a nuclear protein, it is pre-
dominately  chromatin-bound  and  is  enriched  in  te-
lomeric chromatin in S-phase (16, 89). Moreover, de-
spite  possessing  a  robust  NAD+-dependent  au-
to-ADP-ribosyltransferase  activity  (88),  SIRT6  is  a 
highly specific histone 3 deacetylase that targets ace-Int. J. Biol. Sci. 2011, 7 
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tyl-H3K9  and  acetyl-H3K56,  playing  an  important 
role in DNA repair, telomere function, genomic sta-
bility, and cellular senescence (89-91). Human SIRT6 
also  deacetylates  C-terminal  binding  protein  inter-
acting protein (CtIP) and promotes DNA end resec-
tion (92). 
 Recent  studies  using  mouse  models  have  re-
vealed essential roles of SIRT6 in metabolic homeo-
stasis  and  inflammation,  two  heavily  inter-locked 
biological  processes  (Figure  3).  Kawahara  et  al. 
showed that SIRT6 functions at chromatin to attenu-
ate  NF-B  signaling  (93).  SIRT6  interacts  with  the 
RelA subunit of NF-B and deacetylates H3K9 at tar-
get promoters. Deficiency of SIRT6 in mice results in 
increased  NF-B-driven  gene  expression  programs. 
However,  SIRT6 also appears  to  positively  regulate 
Tumor  necrosis  factor  (TNF)  production  at  a 
post-transcriptional step in response to an increase in 
intracellular  NAD+  concentrations  (94),  raising  the 
possibility that SIRT6 may play discrete roles in acute 
and chronic inflammatory responses. SIRT6 is also a 
master  regulator  of  systemic  glucose  metabolism. 
Using a whole-body knockout mouse model, Zhong 
et al. reported that SIRT6 functions as a corepressor of 
the  transcription  factor  Hif1  to  suppress  glucose 
uptake and glycolysis (95). SIRT6 knockout mice are 
hypoglycemic  and  SIRT6-deficient  cells  exhibit  in-
creased  Hif1  activity  with  augmented  glucose up-
take,  along  with  upregulation  of  glycolysis  and  di-
minished  mitochondrial  respiration.  Xiao  et  al.  also 
reported that systemic deletion of SIRT6 in mice re-
sults  in  severe  hypoglycemia,  but  it  appears  that 
SIRT6-deficiency  enhances  both  basal  and  insu-
lin-stimulated glucose uptake through increased in-
sulin signaling and activation of AKT (96). Further, 
studies  using  tissue-specific  SIRT6  knockout  mouse 
models have indicated that SIRT6 regulates metabolic 
homeostasis  both  systemically  and  locally.  For  in-
stance, using a liver-specific SIRT6 knockout mouse 
model,  Kim  et  al.  demonstrated  that  liver-specific 
deletion  of  SIRT6  leads  to  increased  glycolysis  and 
triglyceride  synthesis,  as well as  reduced  fatty  acid 
oxidation,  resulting  in  liver  steatosis  (97).  Neu-
ral-specific deletion of SIRT6 does not lead to hypo-
glycemia (98). Instead, neural SIRT6-null mice exhibit 
postnatal  growth  retardation  due  to  somatotropic 
attenuation through low growth hormone (GH) and 
insulin-like growth factor 1 (IGF1) levels. They grad-
ually reach normal size over time and ultimately be-
come obese. These observations indicate that SIRT6 
regulates  animal  body  growth  through  central  con-
trol, while modulating glucose and lipid metabolism 
at both systemic and local levels (Figure 3). 
 
 
 
 
 
Figure 3. SIRT6 is a critical regulator in genome stability, metabolism, and inflammatory response.  By deacetylation of H3, 
SIRT6 regulates metabolic homeostasis and inflammatory response in peripheral tissues, while functioning as a central 
regulator of somatic growth. 
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Mitochondrial sirtuins in energy metabolism 
In line with the notion that sirtuins are important 
cellular metabolic sensors coupling energy status to 
cellular  functions,  three  of  the  mammalian  sirtuins, 
SIRT3, SIRT4, and SIRT5, are directly localized to mi-
tochondria.  These  double  membrane-bound  orga-
nelles  are  the  “cellular  power  plants”,  consuming 
85-95% of the oxygen used by cells to generate ATP, 
and account for over 90% of reactive oxygen species 
(ROS) generated in cells (99). Mitochondria are also at 
the crossroads between numerous intermediary met-
abolic pathways that function in nutrient adaptation 
in response to environmental nutrient cues. Therefore 
it is not surprising that defects in mitochondrial func-
tions are associated with degenerative diseases, can-
cer, and aging (100). 
 Despite  the  important  localization  of  SIRT3-5, 
mice  with  deletions  of  these  mitochondrial  sirtuins 
lack  obvious  phenotypes  (101),  explaining  why  the 
biochemical and biological functions of these proteins 
have just started to be elucidated (Figure 4). SIRT3, 
the most studied mitochondrial sirtuin, is highly ex-
pressed in metabolically active tissues such as brown 
adipose, muscle, liver, kidney, heart, and brain (102, 
103). Consistent with this expression pattern and its 
mitochondrial localization, deletion of SIRT3 in mice 
leads to striking mitochondrial protein hyperacetyla-
tion  (101).  These  hyperacetylated  proteins  include 
subunits  of  oxidative  phosphorylation  complexes 
(104), metabolic enzymes such as acetyl-CoA synthe-
tase 2 (105, 106), long-chain acyl CoA dehydrogenase 
(LCAD)  (107)  and  3-hydroxy-3-methylglutaryl  CoA 
(HMG-CoA)  synthase  2  (108),  as  well  as  oxidative 
stress reducing enzymes isocitrate dehydrogenase 2 
(IDH2) (36), superoxide dismutase 2 (SOD2) (35), and 
MnSOD (109). A number of recent studies have re-
ported  that  hyperacetylation  of  these mitochondrial 
proteins in SIRT3 deficient mice results in a variety of 
metabolic  abnormalities  including  reduced  ATP 
production,  decreased  rates  of  fatty  acid  oxidation 
and ketone body production, and fatty liver (104, 107, 
108,  110).    In  addition,  SIRT3  also  regulates  mito-
chondrial translation (111), a process that may indi-
rectly impact all mitochondrial pathways.  
 Hyperacetylation of mitochondrial proteins may 
have biological consequences beyond abnormal met-
abolic homeostasis. Using SIRT3-deficient and trans-
genic mouse models, two studies reported that SIRT3 
blocks age-related cardiac hypertrophic response (112, 
113).  Kim et al. showed that SIRT3 is a mitochon-
dria-localized tumor suppressor in response to stress 
(114).  SIRT3  also  protects  in  vitro  fertilized  mouse 
preimplantation  embryos  against  oxidative  stress 
(115).  Furthermore,  two  recent  studies  showed  that 
SIRT3 deficient mice fail to suppress oxidative stress 
and hearing loss in response to CR (35, 36). These ob-
servations demonstrate that SIRT3 can delay the onset 
of a number of oxidative stress-associated pathologies 
in multiple tissues and suggest that SIRT3 may be a 
novel target for these age-associated diseases as well 
as aging itself. However, since SIRT3 null mice dis-
play minimal phenotypes under normal feeding con-
ditions, particularly when they are young (101), much 
work still needs to be done to determine whether the 
effects of SIRT3 deletion on these processes are phys-
iologically relevant, and whether they are direct con-
sequences of particular hyperacetylated mitochondri-
al proteins. Furthermore, it remains to be answered 
whether SIRT3 is required for CR-mediated extension 
of lifespan or it is only a part of CR- elicited anti-aging 
circuits. 
 Unlike  SIRT3,  very  little  is  known  about  the 
functions of SIRT4 and SIRT5. As a sirtuin that only 
displays  detectable  ADP-ribosyltransferase  activity, 
SIRT4 is unique among the mammalian sirtuins (13). 
For example, although SIRT4 is a mitochondrial en-
zyme, it is not enriched in mitochondria-dense tissues 
such as heart and muscle (13). The only known sub-
strate of SIRT4 is glutamate dehydrogenase (GDH), 
and SIRT4 interacts with GDH and suppresses its ac-
tivity via ADP-ribosylation (13). It appears that loss of 
SIRT4 in mice results in increased insulin secretion in 
response  to  glucose  and  amino  acids  (13),  while 
overexpression of SIRT4 in cultured cells suppresses 
insulin secretion (14). SIRT4 also plays a role in the 
regulation of fatty acid oxidation and mitochondrial 
gene expression in liver and muscle cells, although the 
mechanisms  underlying  these  phenotypes  are  still 
unclear (116). SIRT5 has recently been reported as a 
specific deacetylase for carbamoyl phosphate synthe-
tase (CPS1), the rate-limiting first step of the urea cy-
cle in mitochondria (117, 118). Deletion of SIRT5 in 
mice leads to increased acetylation of CPS1 and ele-
vated  levels  of  ammonia  after  prolonged  fasting, 
whereas  SIRT5  transgenic  mice  display  increased 
CPS1  activity  (117).  In  summary,  while  it  appears 
likely that SIRT3 is a major mitochondrial deacetylase 
that helps to prevent non-specific hyperacetylation of 
mitochondrial  proteins  by  acetyl-CoA  over-flood 
during the process of active energy production, SIRT4 
and SIRT5 appear to have specific targets and func-
tions  in  this  organelle.  Further  work  is  needed  to 
identify these SIRT4 and SIRT5 specific targets to elu-
cidate any additional roles these sirtuins possess in 
the regulation of energy metabolism. Int. J. Biol. Sci. 2011, 7 
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Figure 4. Mitochondrial sirtuins in the center of mitochondrial energy metabolism and anti-oxidative stress response. 
Mitochondria are central metabolic organelles for the production of cellular ATP from various nutrients including glucose, 
fatty acids, and amino acids. However, ROS, such as superoxide, are also produced during the oxidative phosphorylation. 
Mitochondria also contain numerous enzymatic complexes involved in intermediary metabolism pathways that function for 
nutrient adaptation and antioxidant defense.  Mitochondrial sirtuins are essential for normal mitochondrial functions 
through interaction and modification of a number of mitochondrial proteins. SIRT3 deacetylates and maintains the normal 
functions of various mitochondrial proteins (blue) involved in fatty acid oxidation, ketogenesis, oxidative phosphorylation, 
antioxidant defense, and amino acid metabolism. GDH (orange) can also be ADP-ribosylated and repressed by SIRT4. SIRT5 
deacetylates and activates CPS1 (green).  This figure is modified from reference 9. 
 
 
Cross talks between sirtuins 
As one of the most important cellular metabolic 
sensors in cells, it has been speculated that the seven 
sirtuins coordinate with each other in various cellular 
compartments  to  actively  monitor  diverse  environ-
mental signals, modulating cellular metabolic activity, 
gene  transcription,  and  genome  stability,  ultimately 
affecting aging. Indeed, perturbation of the activity of 
one sirtuin has been shown to impact the activities of 
other sirtuin members. For example, we reported that 
in  mouse  macrophages,  deletion  of  SIRT1  leads  to 
increased levels of  chromatin-associated SIRT6  near 
the NF-B binding sites, resulting in reduction of local 
acetyl-H3K9 levels,  compensating for the hyperacti-
vation of NF-B induced by SIRT1 deficiency (119). 
Interestingly, this compensatory effect between SIRT1 
and  SIRT6  does  not  appear  to  exist  in  hepatocytes. 
Instead,  deletion  of  SIRT1  causes  50%  reduction  of 
both SIRT6 mRNA and protein levels in the liver (97). 
This is a result of SIRT1 binding to Foxo3a and nuclear 
respiratory factor 1 (NRF-1) on the promoter of SIRT6 
in hepatocytes, directly promoting the expression of 
SIRT6 under both basal and fasting conditions (97). 
Additional  studies  will  be  necessary  to  address 
whether  the  varying  coordination  patterns  between 
these two nuclear sirtuins are related to the different 
metabolic profiles of macrophages and hepatocytes. 
 Intensive  crosstalk  between  nuclear  and  mito-
chondrial sirtuins have also been implied in the liter-
ature. A recent study reported that SIRT3 is a tran-
scriptional target of PGC-1 via an estrogen-related 
receptor  binding  element  (ERRE)  on  its  promoter Int. J. Biol. Sci. 2011, 7 
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(120). As PGC-1 is a direct deacetylation substrate of 
SIRT1 (42), this observation suggests that SIRT1 could 
indirectly modulate the expression of SIRT3 through 
PGC-1 deacetylation. Additionally, Nasrin et al. re-
cently showed that SIRT4 knockdown in hepatocytes 
induces  an  increase  in  fatty  acid  oxidation  through 
SIRT1 (116). Although molecular mechanisms under-
lying these connections remain to be defined, these 
findings  suggest  the  existence  of  a  sirtuin-network 
that may be pivotal in the maintenance of systemic 
metabolic homeostasis.    
Conclusions  
The  discovery  that  overexpression  of  sirtuins 
extends  lifespan  in  lower  model  organisms  has 
evoked  a  flood  of  research  on  their  roles  in  the 
mammalian aging process. The disruption of energy 
metabolism, genome stability, and stress response in 
sirtuin-deficient  mouse  models  demonstrates  that 
mammalian  sirtuins  are  major  contributors  to  the 
delicate  balance  between  metabolism  and  aging. 
Consistent with this notion, small molecule activators 
of  SIRT1,  such  as  the  polyphenol  resveratrol  and 
closely  related  derivatives,  have  shown  promise  as 
therapeutic  agents  for  the  treatment  of  obesity  and 
related  metabolic  diseases  (58,  121,  122),  although 
there were debate on whether these small-molecule 
drugs are direct activators of SIRT1 that function to 
prevent obesity and diabetes (59, 60). Further research 
is needed on the systemic and tissue-specific functions 
of sirtuins in other aspects of the aging process, such 
as stem cell renewal and protein quality control, as 
well  as  on  the  identification  of  novel  targets  and 
modulators of these proteins. Ultimately, these stud-
ies  will  enhance  our  knowledge  of  sirtuin  biology, 
aiding the development novel small molecule modu-
lators of sirtuins to combat age-associated diseases as 
well as aging itself. 
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